Figures
- Fig. 1—
Frequency of adverse effects attributed to linezolid during combined treatment against multidrug-resistant/extensively drug-resistant tuberculosis at different time-points after treatment initiation with a 600 mg q.d. or a 600 mg b.i.d. regimen (denominator is the total number of individuals per group). □: 600 mg q.d., n = 28; ▓: 600 mg b.i.d., n = 57.
Tables
- Table 1—
Safety and tolerability of linezolid in patients treated for multidrug-resistant/extensively drug-resistant tuberculosis in Belarus, Germany, Italy and Switzerland, 2001–2007
Total 600 mg q.d. 600 mg b.i.d. p-value# Patients Total n 85 28 57 No adverse event 50 (58.8) 24 (85.7) 26 (45.6) 0.0004 Any adverse event 35 (41.2) 4 (14.3) 31 (54.4) 0.0004 Minor 8 (9.4) 0 8 (14) Major 27 (31.8) 4 (14.3) 23 (40.4) 0.01 Episodes Total n 52 5 47 Anaemia 23 (44.2) 3 (60) 20 (42.5) 0.44 Thrombocytopenia 7 (13.5) 0 (0) 7 (14.9) Nausea/vomiting 4 (7.7) 1 (20) 3 (6.4) 0.25 Polyneuropathy 3 (5.8) 1 (20) 2 (4.3) 0.13 Others 15 (28.8) 0 (0) 15 (31.9) Data are presented as n (%), unless otherwise stated. #: comparison between 600 mg q.d. group and 600 mg b.i.d. group.
- Table 2—
Comparison of efficacy end-points for the treatment of multidrug-resistant/extensively drug-resistant tuberculosis with or without linezolid in cases with known outcome
Linezolid No linezolid p-value Patients n 45 110 Sputum smear conversion time days Mean±sd 102.9±74 65.4±80.1 0.007 n (%) 31 (69) 59 (54) Culture conversion time days Mean±sd 109±71 69±63 0.0007 n (%) 39 (87) 86 (78) Treatment outcome Success 36 (80.0) 90 (81.8) 0.88 Cured 23 (51.1) 75 (68.2) 0.04 Completed 13 (28.9) 15 (13.6) 0.02 Failure 1 (0.9) Death 9 (20) 19 (17.3) 0.65 Data are presented as n (%), unless otherwise stated.
- Table 3—
Proportion of converters, according to the number of antituberculous drugs to which isolates were resistant, among patients treated with and without linezolid(LZD) in Belarus, Germany, Italy and Switzerland, 2001–2007
Drug resistance n Sputum smear conversion Culture conversion LZD treated No LZD p-value LZD treated No LZD p-value <5 6/9 (66.7) 35/59 (59.3) 0.68 8/9 (88.9) 50/59 (84.7) 0.75 5–7 16/26 (61.5) 23/43 (53.5) 0.51 22/26 (84.6) 34/43 (79.1) 0.6 >7 9/10 (90) 1/8 (12.5) 0.0009 9/10 (90) 2/8 (25) 0.004 Total 31/45 (68.9) 59/110 (53.6) 0.07 39/45 (86.7) 86/110 (78.2) 0.22 Data are presented as n/n (%), unless otherwise stated.
- Table 4—
Logistic regression analysis of potential independent variables associated with adverse treatment outcome(failure or death) in multidrug-resistant/extensively drug-resistant tuberculosis (XDR-TB) cases
Variables Crude odds ratio p-value Adjusted odds ratio p-value Sex male 1.11 (0.43–2.85) 0.82 1.8 (0.56–5.78) 0.32 Increasing age yrs 1.03 (1.008–1.06) 0.01 1.03 (1.003–1.07) 0.03 Previous treatment >30 days 1.8 (0.76–4.27) 0.18 1.01 (0.38–2.65) 0.98 Resistance to >5 drugs 2.67 (1.17–6.1) 0.01 1.78 (0.59–5.34) 0.29 Linezolid treatment 0.88 (0.36–2.13) 0.79 1.1 (0.39–3.1) 0.85 XDR-TB 11.6 (3.2–42.05) <0.0001 8.3 (1.74–40.28) 0.008 Data are presented as odds ratio (95% confidence interval), unless otherwise stated.
